U.S. FDA approves WINREVAIR label update with Phase 3 HYPERION data
AI Summary- U.S. FDA approved a WINREVAIR label update incorporating HYPERION trial data.
- Phase 3 HYPERION evaluated adults recently diagnosed with pulmonary arterial hypertension.
- WINREVAIR contains sotatercept-csrk and is used in WHO Group 1 pulmonary hypertension context.